曹德良博士 / Dr. Deliang Cao

湖南萊拓福生物科技有限公司董事長、法人、首席科學家，前美國南伊利諾伊大學醫(yī)學院醫(yī)學微生物學、免疫學和細胞生物學系、Simmons腫瘤研究所終身教授(Tenured)，博士生導師。國家特聘專家，湖南省“百人計劃”專家，“芙蓉學者獎勵計劃”講座教授。

曹博士是AKR1B10基因發(fā)現(xiàn)者，AKR1B10原發(fā)性肝癌診斷試劑盒《醛酮還原酶1B10測定試劑盒》（埃克欣® AKR）發(fā)明者；發(fā)表SCI收錄科研學術論文110余篇，其中AKR1B10 相關SCI 論文 32 篇，AKR1B10 單篇最高被引355次，是全球AKR1B10研究的引領者。獲得美國發(fā)明專利3項，中國發(fā)明專利4項，申報在審發(fā)明專利4項。

曹博士于2021年9月全職回國工作，兼任南華大學和湖南中醫(yī)藥大學特聘教授；肝癌早診早治湖南省工程研究中心主任、首席科學家。

Chairman, legal person and chief scientist of Hunan Light of Life Biotechnology Co., Ltd. a former tenured professor and doctoral supervisor in Department of Medical Microbiology, Immunology and Cell Biology & Simmons Cancer Institute at Southern Illinois University School of Medicine. He was awarded the "Hundred Talents Program" Scholars of Hunan Province in 2013 and the "Furong Scholars Award Program" Chair Professor of Hunan Province in 2020.

Dr. Cao is the discoverer of the AKR1B10 gene and the inventor of the AKR1B10 primary liver cancer diagnostic product "Aldo-keto Reductase 1B10 Assay Kit"; he has published 102 scientific research papers incited in SCI, including 32 SCI papers in AKR1B10 with a single AKR1B10 paper Cited up to 355 times. Dr. Cao is the global leader in AKR1B10 research. He has obtained 3 American invention patents and 4 Chinese invention patents with 4 patents under peer review.

Professor Cao has resigned all titles in USA and been back to China full-time in September 2021, and he also serves as a Distinguished Professor at the University of South China and Hunan University of Traditional Chinese Medicine. Dr. Cao is committed to marketing of self-developed patents for the medical health of humans.